Oura Health filed its S-1 prospectus this week with subscription and partnership revenue rising 34% year-over-year, outstripping hardware unit growth by a material margin. The Finnish company, known for titanium sleep-tracking rings priced at $299 to $549, now derives more than half its gross profit from recurring sources rather than device sales. The shift arrived without the usual fanfare of a business model pivot.

The prospectus shows subscription membership revenue reached $87 million in the trailing twelve months, up from $65 million the prior year. Membership costs $5.99 monthly after a complimentary first month. Retention sits at 82% past the trial period, and average subscriber lifetime extends 41 months. More notable: B2B partnership revenue, primarily from employers offering Oura as a wellness benefit, grew 61% to $34 million. Corporate buyers now account for 22% of new ring activations, a figure that was 9% eighteen months ago.

This matters because wearables companies typically die on hardware margin compression. Fitbit burned through $800 million in market cap before Google acquired it at a discount. Whoop raised $400 million in venture capital and still hasn't filed. Oura's path diverges: gross margin on subscriptions runs 89%, compared to 37% on devices. The company reached EBITDA breakeven in Q3 2024 and generated $19 million in free cash flow over the trailing twelve months. Revenue per user climbed $47 year-over-year to $312, driven entirely by subscription attachment and corporate account expansion.

The B2B channel introduced structural advantages competitors lack. Employers pay upfront for multi-year commitments, often covering both hardware and subscriptions. Oura books the hardware revenue immediately and recognizes subscription revenue ratably. Corporate churn runs 11% annually versus 18% for consumer direct. Partnership deals with insurers and health systems, disclosed in the risk factors section, suggest Oura is positioning the ring as a reimbursable medical device in select markets. That would shift another revenue stream from consumer discretionary to third-party payer.

Operators should track three data points in coming quarters. First, corporate penetration rate—if B2B reaches 30% of activations by mid-2025, the revenue model becomes defensible against cash-burning competitors. Second, international expansion velocity—Oura launched in Japan and South Korea in Q4 2024, markets where wearable adoption runs 40% higher than the U.S. Third, FDA clearance timing for atrial fibrillation detection, filed in September 2024. Clearance would unlock HSA/FSA eligibility and potential insurance reimbursement pathways, worth $80 to $120 incremental revenue per device.

The IPO pricing has not been disclosed. The company last raised at a $2.55 billion valuation in October 2023. On a revenue multiple basis, if Oura prices near 6x to 8x trailing revenue, that implies a valuation range of $2.1 billion to $2.8 billion, assuming total revenue of $350 million. Underwriters are Goldman Sachs and Morgan Stanley. The roadshow begins mid-February, with pricing expected late March.